Logotype for Beam Therapeutics Inc

Beam Therapeutics (BEAM) Proxy filing summary

Event summary combining transcript, slides, and related documents.

Logotype for Beam Therapeutics Inc

Proxy filing summary

17 Apr, 2026

Voting matters and shareholder proposals

  • Election of three Class III director nominees for three-year terms ending at the 2029 annual meeting.

  • Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

  • Advisory approval of named executive officer compensation (say-on-pay).

  • Proxies may vote on other business arising at the meeting or any adjournment.

Board of directors and corporate governance

  • Board recommends voting for all three director nominees: John Evans, John Maraganore, Ph.D., and Christi Shaw.

  • Directors to serve three-year terms if elected, expiring at the 2029 annual meeting.

Executive compensation and say-on-pay

  • Advisory vote to approve compensation of named executive officers is included as a voting item.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more